Pegfilgrastim

Current and future perspectives in the treatment of chemotherapy-induced neutropenia

Riccardo Ricotta, Giulio Cerea, Ilaria Schiavetto, Maria Rosaria Maugeri, Paolo Pedrazzoli, Salvatore Siena

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Myeloid colony-stimulating factors (granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its potentially life-threatening complications. Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have demonstrated that a single, fixed, subcutaneous dose of pegfilgrastim is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells.

Original languageEnglish
Pages (from-to)667-676
Number of pages10
JournalFuture Oncology
Volume2
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Neutropenia
Drug Therapy
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Colony-Stimulating Factors
Hematopoietic Stem Cell Transplantation
Therapeutics
Granulocyte-Macrophage Colony-Stimulating Factor
Neutrophils
Clinical Trials
Safety
Injections
pegfilgrastim
Incidence
Infection
Neoplasms
Filgrastim

Keywords

  • Colony-stimulating factor
  • Granulocyte colony-stimulating factor
  • Hematopoietic growth factor
  • Neutropenia
  • Pegfilgrastim

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pegfilgrastim : Current and future perspectives in the treatment of chemotherapy-induced neutropenia. / Ricotta, Riccardo; Cerea, Giulio; Schiavetto, Ilaria; Maugeri, Maria Rosaria; Pedrazzoli, Paolo; Siena, Salvatore.

In: Future Oncology, Vol. 2, No. 6, 12.2006, p. 667-676.

Research output: Contribution to journalArticle

Ricotta, Riccardo ; Cerea, Giulio ; Schiavetto, Ilaria ; Maugeri, Maria Rosaria ; Pedrazzoli, Paolo ; Siena, Salvatore. / Pegfilgrastim : Current and future perspectives in the treatment of chemotherapy-induced neutropenia. In: Future Oncology. 2006 ; Vol. 2, No. 6. pp. 667-676.
@article{167f4273846e4713bc840edda13efd44,
title = "Pegfilgrastim: Current and future perspectives in the treatment of chemotherapy-induced neutropenia",
abstract = "Myeloid colony-stimulating factors (granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its potentially life-threatening complications. Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have demonstrated that a single, fixed, subcutaneous dose of pegfilgrastim is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells.",
keywords = "Colony-stimulating factor, Granulocyte colony-stimulating factor, Hematopoietic growth factor, Neutropenia, Pegfilgrastim",
author = "Riccardo Ricotta and Giulio Cerea and Ilaria Schiavetto and Maugeri, {Maria Rosaria} and Paolo Pedrazzoli and Salvatore Siena",
year = "2006",
month = "12",
doi = "10.2217/14796694.2.6.667",
language = "English",
volume = "2",
pages = "667--676",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Pegfilgrastim

T2 - Current and future perspectives in the treatment of chemotherapy-induced neutropenia

AU - Ricotta, Riccardo

AU - Cerea, Giulio

AU - Schiavetto, Ilaria

AU - Maugeri, Maria Rosaria

AU - Pedrazzoli, Paolo

AU - Siena, Salvatore

PY - 2006/12

Y1 - 2006/12

N2 - Myeloid colony-stimulating factors (granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its potentially life-threatening complications. Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have demonstrated that a single, fixed, subcutaneous dose of pegfilgrastim is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells.

AB - Myeloid colony-stimulating factors (granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its potentially life-threatening complications. Pegfilgrastim is a novel recombinant human G-CSF pharmaceutically developed by covalent binding of a polyethylene glycol molecule to the N-terminal sequence of filgrastim. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have demonstrated that a single, fixed, subcutaneous dose of pegfilgrastim is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells.

KW - Colony-stimulating factor

KW - Granulocyte colony-stimulating factor

KW - Hematopoietic growth factor

KW - Neutropenia

KW - Pegfilgrastim

UR - http://www.scopus.com/inward/record.url?scp=33845619831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845619831&partnerID=8YFLogxK

U2 - 10.2217/14796694.2.6.667

DO - 10.2217/14796694.2.6.667

M3 - Article

VL - 2

SP - 667

EP - 676

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -